<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01110837</url>
  </required_header>
  <id_info>
    <org_study_id>#09-3232</org_study_id>
    <nct_id>NCT01110837</nct_id>
  </id_info>
  <brief_title>Repeat Dose Nasal Allergen Challenge</brief_title>
  <official_title>Repeat Dose Nasal Allergen Challenge: Development of a Model to Investigate the Cellular and Inflammatory Changes That Occur in Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Joseph's Healthcare Hamilton</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>McMaster University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      What happens in the nose during an allergic reaction? Are there changes that a new drug could&#xD;
      treat? What is the best way to test new drugs?The response of the nose to being exposed to&#xD;
      cat allergen in someone who is allergic to cats. Symptoms, level of nasal blockage and cell&#xD;
      and chemical changes that occur in the nose will be studied before and after being exposed to&#xD;
      cat allergen. The investigators will also to see if giving repeated doses of allergen&#xD;
      increases the response.Allergic rhinitis is a very common illness. There are over 500 million&#xD;
      patients worldwide. It can increase the severity of associated asthma. Currently available&#xD;
      drugs do not completely treat the symptoms. New treatments need to be found. A way of testing&#xD;
      these drugs is very important. This study will investigate causes of the symptoms that occur&#xD;
      in allergic rhinitis. It will also validate a proposed model to test new drugs. the Study&#xD;
      Hypothesis is that a model of nasal allergen challenge shows an increased response (priming)&#xD;
      with repeat challenges as determined by changes in nasal peak inspiratory flow.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>April 2010</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">April 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in peak nasal inspiratory flow following repeat allergen challenge</measure>
    <time_frame>1 year</time_frame>
    <description>The peak nasal inspiratory flow will be measured using a hand-held peak flow meter, and changes will be measured following repeated allergen challenge.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Allergen</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Allergen</intervention_name>
    <description>Allergen nasal challenge</description>
    <arm_group_label>Allergen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo challenge</intervention_name>
    <description>Placebo nasal challenge</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male and female subjects aged over 18 able to understand and sign the written consent&#xD;
             form.&#xD;
&#xD;
          2. Able to comply with study procedures and protocol.&#xD;
&#xD;
          3. Positive skin prick test (wheal difference ≥ 3mm compared to negative control) to cat&#xD;
             at or within 12 months preceding the screening visit.&#xD;
&#xD;
          4. Clear history of nasal symptoms on exposure to cats.&#xD;
&#xD;
          5. Otherwise healthy with no other health problems, other than mild asthma controlled by&#xD;
             intermittent β2-agonist use, that may prevent the subject participating in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Presence of perennial rhinitis or seasonal allergic rhinitis.&#xD;
&#xD;
          2. TNSS &lt; 2 at screening&#xD;
&#xD;
          3. Viral URTI within the 2 weeks prior to screening.&#xD;
&#xD;
          4. Current smoker or history of smoking within the previous 3 months.&#xD;
&#xD;
          5. Presence of any structural nasal abnormalities or nasal polyps on examination, a&#xD;
             history of frequent nose bleeding, nasal surgery within the previous 3 months.&#xD;
&#xD;
          6. Use of concomitant medication that could affect responses to nasal challenge (e.g.&#xD;
             corticosteroids, decongestants, anti-histamines) or any other nasally applied&#xD;
             medication within 2 weeks prior to screening.&#xD;
&#xD;
          7. Participation in any other clinical trials within the previous 3 months.&#xD;
&#xD;
          8. Use of inhaled corticosteroids within the 2 months prior to screening.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Neighbour, MB BS</last_name>
    <role>Principal Investigator</role>
    <affiliation>McMaster University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Helen Neighbour, MB BS PhD</last_name>
    <phone>905-522-1155</phone>
    <phone_ext>32145</phone_ext>
    <email>neighbh@mcmaster.ca</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Joseph's Healthcare</name>
      <address>
        <city>Hamitlon</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 23, 2010</study_first_submitted>
  <study_first_submitted_qc>April 26, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2010</study_first_posted>
  <last_update_submitted>October 31, 2012</last_update_submitted>
  <last_update_submitted_qc>October 31, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 1, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic rhinitis</keyword>
  <keyword>Allergen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

